Search

Author/Creator Topp, Max S

1. Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs. Issue 6 (11th August 2015)

Authors:
Berges, Carsten; Bedke, Tanja; Stuehler, Claudia; Khanna, Nina; Zehnter, Sarah; Kruhm, Michaela; Winter, Nadine; Bargou, Ralf C; Topp, Max S; Einsele, Hermann; Chatterjee, Manik
Journal:
Journal of leukocyte biology
Issue:
Volume 98:Issue 6(2015)
Page Start:
1091
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Distinct and complementary roles for Aspergillus fumigatus‐specific Tr1 and Foxp3+ regulatory T cells in humans and mice. Issue 8 (13th May 2014)

Authors:
Bedke, Tanja; Iannitti, Rossana G; De Luca, Antonella; Giovannini, Gloria; Fallarino, Francesca; Berges, Carsten; Latgé, Jean‐Paul; Einsele, Hermann; Romani, Luigina; Topp, Max S
Journal:
Immunology and cell biology
Issue:
Volume 92:Issue 8(2014)
Page Start:
659
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Issue 12 (December 2017)

Authors:
Eichenauer, Dennis A; Plütschow, Annette; Kreissl, Stefanie; Sökler, Martin; Hellmuth, Johannes C; Meissner, Julia; Mathas, Stephan; Topp, Max S; Behringer, Karolin; Klapper, Wolfram; Kuhnert, Georg; Dietlein, Markus; Kobe, Carsten; Fuchs, Michael; Diehl, Volker; Engert, Andreas; Borchmann, Peter
Journal:
Lancet oncology
Issue:
Volume 18:Issue 12(2017:Dec.)
Page Start:
1680
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Issue 4 (April 2021)

Authors:
Gillessen, Sarah; Plütschow, Annette; Fuchs, Michael; Markova, Jana; Greil, Richard; Topp, Max S; Meissner, Julia; Zijlstra, Josée M; Eichenauer, Dennis A; Bröckelmann, Paul J; Diehl, Volker; Borchmann, Peter; Engert, Andreas; von Tresckow, Bastian
Journal:
Lancet
Issue:
Volume 8:Issue 4(2021)
Page Start:
e278
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Issue 10299 (7th August 2021)

Authors:
Shah, Bijal D; Ghobadi, Armin; Oluwole, Olalekan O; Logan, Aaron C; Boissel, Nicolas; Cassaday, Ryan D; Leguay, Thibaut; Bishop, Michael R; Topp, Max S; Tzachanis, Dimitrios; O'Dwyer, Kristen M; Arellano, Martha L; Lin, Yi; Baer, Maria R; Schiller, Gary J; Park, Jae H; Subklewe, Marion; Abedi, Me...
Journal:
Lancet
Issue:
Volume 398:Issue 10299(2021)
Page Start:
491
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Issue 5 (May 2022)

Authors:
Bannerji, Rajat; Arnason, Jon E; Advani, Ranjana H; Brown, Jennifer R; Allan, John N; Ansell, Stephen M; Barnes, Jeffrey A; O'Brien, Susan M; Chávez, Julio C; Duell, Johannes; Rosenwald, Andreas; Crombie, Jennifer L; Ufkin, Melanie; Li, Jingjin; Zhu, Min; Ambati, Srikanth R; Chaudhry, Aafia; Lowy...
Journal:
Lancet
Issue:
Volume 9:Issue 5(2022)
Page Start:
e327
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Issue 9976 (11th April 2015)

Authors:
Behringer, Karolin; Goergen, Helen; Hitz, Felicitas; Zijlstra, Josée M; Greil, Richard; Markova, Jana; Sasse, Stephanie; Fuchs, Michael; Topp, Max S; Soekler, Martin; Mathas, Stephan; Meissner, Julia; Wilhelm, Martin; Koch, Peter; Lindemann, Hans-Walter; Schalk, Enrico; Semrau, Robert; Kriz, Jan;...
Journal:
Lancet
Issue:
Volume 385:Issue 9976(2015)
Page Start:
1418
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Issue 6 (June 2021)

Authors:
Kreissl, Stefanie; Goergen, Helen; Buehnen, Ina; Kobe, Carsten; Moccia, Alden; Greil, Richard; Eichenauer, Dennis A; Zijlstra, Josée M; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Soekler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst, Thomas; Topp, M...
Journal:
Lancet
Issue:
Volume 8:Issue 6(2021)
Page Start:
e398
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Issue 2 (February 2021)

Authors:
Borchmann, Peter; Plütschow, Annette; Kobe, Carsten; Greil, Richard; Meissner, Julia; Topp, Max S; Ostermann, Helmut; Dierlamm, Judith; Mohm, Johannes; Thiemer, Julia; Sökler, Martin; Kerkhoff, Andrea; Ahlborn, Miriam; Halbsguth, Teresa V; Martin, Sonja; Keller, Ulrich; Balabanov, Stefan; Pabst, ...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 2(2021)
Page Start:
223
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗